| Bioactivity | Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[1][2]. | ||||||||||||
| In Vivo | Alfuzosin hydrochloride (10 mg/kg, p.o.; single) potently antagonizes phenylephrine-induced increases in urethral and arterial pressures up to 6 hours post dosing[1]. Animal Model: | ||||||||||||
| Name | Alfuzosin | ||||||||||||
| CAS | 81403-80-7 | ||||||||||||
| Formula | C19H27N5O4 | ||||||||||||
| Molar Mass | 389.45 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Martin DJ, et al. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci. 1998;63(3):169-76. [2]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. |